Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial
| Autor: | Lisa B. Leypoldt, Markus Munder, Anne Marie Asemissen, Hartmut Goldschmidt, Carsten Bokemeyer, Raphael Lutz, Ullrich Graeven, Axel Benner, Britta Besemer, Rudolf Peceny, Manola Zago, Martin Görner, Mathias Hänel, Hans Salwender, Christoph Mann, Katja Weisel, Diana Tichy, Peter Staib, Yon-Dschun Ko, Anna Jauch, Hans Christian Reinhardt, Igor Wolfgang Blau |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
Isatuximab Myeloma Phase II trials Cancer Research medicine.medical_specialty business.industry Medizin Front line Hematology medicine.disease Interim analysis Carfilzomib chemistry.chemical_compound chemistry Internal medicine medicine business Multiple myeloma Dexamethasone Lenalidomide medicine.drug |
| Zdroj: | Leukemia, 36(3):885888 |
| ISSN: | 1476-5551 0887-6924 |
| DOI: | 10.1038/s41375-021-01431-x |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink